Evidence map›Paper›PMID 24634497›Full record

ArticleThe Journal of infectious diseases2014

Understanding the mechanisms controlling Leishmania amazonensis infection in vitro: the role of LTB4 derived from human neutrophils.

Natalia Machado Tavares, Théo Araújo-Santos, Lilian Afonso, Paula Monalisa Nogueira, Ulisses Gazos Lopes, Rodrigo Pedro Soares, Patrícia Torres Bozza, Christianne Bandeira-Melo, Valeria Matos Borges, Cláudia Brodskyn

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 71 citations in OpenAlex.

  1. Review
  2. Frontiers in immunology · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Fatty Acid Composition and Metabolism inInternational journal of molecular sciences · 2023
    Review
  12. Leukotrienes in Innate Immunity: Still Underappreciated after All These Years?Journal of immunology (Baltimore, Md. : 1950) · 2023
    Review
  13. Article
  14. Article
  15. Frontiers in cellular and infection microbiology · 2022
    Article
  16. Lipophosphoglycan From Dermotropic New WorldFrontiers in cellular and infection microbiology · 2022
    Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Natalia Machado TavaresGonçalo Moniz Research Center, Oswaldo Cruz Foundation-FIOCRUZ Federal University of Bahia-UFBA, Salvador, Brazil.
Théo Araújo-SantosGonçalo Moniz Research Center, Oswaldo Cruz Foundation-FIOCRUZ Federal University of Bahia-UFBA, Salvador, Brazil.
Lilian AfonsoGonçalo Moniz Research Center, Oswaldo Cruz Foundation-FIOCRUZ.
Paula Monalisa NogueiraRené Rachou Research Center, Oswaldo Cruz Foundation-FIOCRUZ, Belo Horizonte, Brazil.
Ulisses Gazos LopesCarlos Chagas Filho Institute-Federal University of Rio de Janeiro-UFRJ.
Rodrigo Pedro SoaresRené Rachou Research Center, Oswaldo Cruz Foundation-FIOCRUZ, Belo Horizonte, Brazil.
Patrícia Torres BozzaImmunopharmacology Laboratory, Oswaldo Cruz Institute-Oswaldo Cruz Foundation-FIOCRUZ, Rio de Janeiro, Brazil.
Christianne Bandeira-MeloCarlos Chagas Filho Institute-Federal University of Rio de Janeiro-UFRJ.
Valeria Matos BorgesGonçalo Moniz Research Center, Oswaldo Cruz Foundation-FIOCRUZ Federal University of Bahia-UFBA, Salvador, Brazil National Institute of Science and Technology for Immunology Investigation (iii-INCT), Salvador, Bahia, Brazil.
Cláudia BrodskynGonçalo Moniz Research Center, Oswaldo Cruz Foundation-FIOCRUZ Federal University of Bahia-UFBA, Salvador, Brazil National Institute of Science and Technology for Immunology Investigation (iii-INCT), Salvador, Bahia, Brazil.
Fundação Oswaldo Cruz · BRUniversidade Federal da Bahia · BRFundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro · BRUniversidade Federal do Rio de Janeiro · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neutrophils are rapidly recruited to the site of Leishmania infection and play an active role in capturing and killing parasites. They are the main source of leukotriene B4 (LTB4), a potent proinflammatory lipid mediator. However, the role of LTB4 in neutrophil infection by Leishmania amazonensis is not clear. In this study, we show that L. amazonensis or its lipophosphoglycan can induce neutrophil activation, degranulation, and LTB4 production. Using pharmacological inhibitors of leukotriene synthesis, our findings reveal an LTB4-driven autocrine/paracrine regulatory effect. In particular, neutrophil-derived LTB4 controls L. amazonensis killing, degranulation, and reactive oxygen species production. In addition, L. amazonensis infection induces an early increase in Toll-like receptor 2 expression, which facilitates parasite internalization. Nuclear factor kappa B (NFkB) pathway activation represents a required upstream event for L. amazonensis-induced LTB4 synthesis. These leishmanicidal mechanisms mediated by neutrophil-derived LTB4 act through activation of its receptor, B leukotriene receptor 1 (BLT1).

Indexed as

Antigens, SurfaceHumansLeishmania mexicanaLeishmaniasis, CutaneousLeukotriene B4NeutrophilsNF-kappa BReactive Oxygen SpeciesReceptors, Leukotriene B4Toll-Like Receptor 2Antigens, SurfaceLeukotriene B4LTB4R protein, humanNF-kappa BReactive Oxygen SpeciesReceptors, Leukotriene B4Toll-Like Receptor 2human neutrophilsLeishmania amazonensisleukotriene B4LPGTLR2; NFkB

Identifiers

PMID24634497
PMCPMC4111911
OpenAlexW2149492098

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.